menu search

Agios pharmaceuticals is a buy on coming revenue ramp

Agios sold its first successful commercial drug to Servier for $2 billion. Launch of second drug, pyrukynd...

July 26, 2022, 12:32 am

Fda approves agios' mitapivat as first disease-modifying therapy for genetic blood disorder

The FDA approved Agios Pharmaceuticals Inc's (NASDAQ: AGIO) pyrukynd (mitapivat) for hemolytic anemi...

February 18, 2022, 5:41 am

Fda approves agios' mitapivat as first disease-modifying therapy for genetic blood disorder

The FDA approved Agios Pharmaceuticals Inc's (NASDAQ: AGIO) pyrukynd (mitapivat) for hemolytic anemi...

February 18, 2022, 5:41 am

Fda approves agios' mitapivat as first disease-modifying therapy for genetic blood disorder

The FDA approved Agios Pharmaceuticals Inc's (NASDAQ: AGIO) pyrukynd (mitapivat) for hemolytic anemi...

February 18, 2022, 5:41 am


Search within

Pages Search Results: